Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CRISPR Therapeutics AG Director's Dealing 2017

Nov 13, 2017

30936_dirs_2017-11-13_0d9d071e-b351-4033-8531-0675911fdf85.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2017-11-13

Reporting Person: TOMSICEK MICHAEL JOHN (Chief Financial Officer)